The following table presents unaudited quarterly consolidated operating results for each of our last eight fiscal quarters. The information below has been prepared on a basis consistent with our audited consolidated financial statements (in millions, except per share amounts).



Fiscal Year 2015	First Quarter ⁽²⁾		Second Quarter ⁽³⁾		Third Quarter ⁽⁴⁾			Fourth Quarter ⁽⁵⁾
Net sales	$	951.5	$	1,071.7	$	1,049.1		$	1,531.6
Gross profit	$	321.8	$	383.8	$	378.8		$	628.1
Net income (loss)	$	96.3	$	70.2	$	(94.9	)	$	56.4
Earnings (loss) per share⁽¹⁾:
Basic	$	0.72	$	0.52	$	(0.67	)	$	0.39
Diluted	$	0.72	$	0.51	$	(0.67	)	$	0.38
Weighted average shares outstanding
Basic	133.9		136.3		140.8			146.3
Diluted	134.4		136.8		140.8			146.8

⁽¹⁾ The sum of individual per share amounts may not equal due to rounding.


⁽²⁾	Includes acquisition costs of $1.1 million, restructuring charges of $1.7 million, equity method investment losses of $3.1 million, and a $1.2 million investment distribution.

⁽³⁾

Includes restructuring charges of $2.4 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, Omega transaction expenses of $17.8 million, losses on derivatives associated with the Omega acquisition of $64.7 million, equity method investment losses of $3.0 million, income from transfer of rights agreement of $12.5 million, and $9.6 million loss on extinguishment of debt.


⁽⁴⁾	Includes acquisition costs totaling $2.0 million, an increase in litigation accrual of $2.0 million, restructuring charges of $1.1 million, Omega financing fees of $18.6 million, and losses on derivatives associated with the Omega acquisition of $258.2 million.

⁽⁵⁾

Includes legal and consulting fees related to our defense against Mylan N.V. of $13.4 million, acquisition costs of $18.5 million, goodwill impairment of $6.8 million, losses on derivatives terminated with extinguishment of associated debt and associated with hedging the pending GSK acquisition of $5.5 million, losses on equity method investments of $3.5 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and an initial payment made in connection with an R&D agreement of $18.0 million.



Fiscal Year 2014	First Quarter ⁽²⁾		Second Quarter ⁽³⁾			Third Quarter ⁽⁴⁾		Fourth Quarter ⁽⁵⁾
Net sales	$	933.4	$	979.0		$	1,004.2	$	1,144.2
Gross profit	$	356.3	$	360.7		$	315.0	$	415.7
Net income (loss)	$	111.4	$	(86.0	)	$	48.1	$	131.7
Earnings (loss) per share⁽¹⁾:
Basic	$	1.18	$	(0.87	)	$	0.36	$	0.98
Diluted	$	1.18	$	(0.87	)	$	0.36	$	0.98
Weighted average shares outstanding
Basic	94.2		98.7			133.7		133.8
Diluted	94.7		98.7			134.3		134.3


⁽¹⁾	The sum of individual per share amounts may not equal due to rounding.


⁽²⁾	Includes Elan transactions costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.


⁽³⁾	Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D totaling $6.0 million related to Paddock and Rosemont.


⁽⁴⁾	Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.


⁽⁵⁾	Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.